• Email Us: [email protected]
  • Contact Us: +1 718 874 1545
  • Skip to main content
  • Skip to primary sidebar

Medical Market Report

  • Home
  • All Reports
  • About Us
  • Contact Us

New Monoclonal Antibody “Highly Effective” For Kids With Severe Eczema

September 22, 2022 by Deborah Bloomfield

New research that has used a biologic drug to treat infants and kids with severe eczema has shown huge promise in an early trial. By using this monoclonal antibody treatment in kids, the researchers even speculate that it might be able to save them from developing other allergies beyond eczema.

After a 16-week course of the drug, over half of the kids younger than 6 years with moderate-to-severe eczema experienced a 75 percent reduction in symptom severity, according to the new study. They also itched significantly less and slept better.

Advertisement

This, no doubt, also produced some very happy parents. 

“Preschoolers who are constantly scratching, awake multiple times a night with their parents, irritable and markedly curtailed in their ability to do what other children their ages can do improved to the extent that they sleep through the night, change their personalities and have a normal life – as babies and children should,” Amy Paller, lead study author, the chair and Walter J. Hamlin Professor of Dermatology, and an attending physician at Ann & Robert H. Lurie Children’s Hospital of Chicago, said in a statement. 

In the trial, the children received the drug through a simple injection every four weeks at over 30 hospitals, clinics, and academic institutions across Europe and North America. It involved a total of 162 participants, 83 of whom were given the drug and 79 who were unknowingly given a placebo.

Advertisement

The drug in question is dupilumab, which is a monoclonal antibody, a type of lab-made protein that can bind to certain targets in the body, such as an antigen on a cell.

People with eczema have an overactive immune system that overreacts to allergens, triggering the production of chemical messengers known as interleukins, which results in inflammation. In the case of dupilumab, it binds to and blocks certain interleukins, thereby making them useless. 

While the treatment has already been approved for use in adults by the FDA, this is the first trial of its kind to be carried out in infants as young as six months old. Thanks to the results, dupilumab has now become available to infants and preschoolers aged six months to five years.

Advertisement

“Up to now, all we have had to treat more severe eczema is immune-suppressing medications, such as oral steroids, which we try to avoid in children because they are associated with so many side effects and thus are not a preferred treatment for a chronic skin disease,” Paller explained. 

“The potential long-term impact on the development of the immune system in young children is also of concern with these immunosuppressants,” she added.

It’s estimated that 31.6 million people (10.1 percent) in the US have some form of eczema. For around two-thirds of people, it’s an uncomfortable condition that can be managed with steroid ointment and moisturizers, but for the remaining one-third, it can be so severe that it has to be tackled with more intense treatment. 

Advertisement

Due to the fact that dupilumab acts on peoples’ immune response, it’s even speculated that the treatment might have broader benefits and could perhaps prevent children from developing other allergies.

“By treating more aggressively to calm the immune system activation in these young children with early, severe eczema, we may also reduce the risk of them developing a range of allergic problems, changing their life beyond improving eczema,” Paller explained. “These associated allergic issues most often begin after the eczema starts.” 

The study was published in the journal The Lancet.

Deborah Bloomfield
Deborah Bloomfield

Related posts:

  1. Australia’s RBA optimistic on economy, but rates to stay low until 2024
  2. Indonesia govt, key parliamentary body set 2022 GDP growth target at 5.2%
  3. La Palma volcano spurts again as lava nears the sea
  4. Private equity is ready to take MSP consolidation to the next level

Source Link: New Monoclonal Antibody "Highly Effective" For Kids With Severe Eczema

Filed Under: News

Primary Sidebar

  • The Bizarre 1997 Experiment That Made A Frog Levitate
  • There’s A Very Good Reason Why October 1582 On Your Phone Is Missing 10 Days
  • Skynet-1A: Military Spacecraft Launched 56 Years Ago Has Been Moved By Persons Unknown
  • There’s A Simple Solution To Helping Avoid Erectile Dysfunction (But You’re Not Going To Like It)
  • Interstellar Object 3I/ATLAS May Be 10 Billion Years Old, This Rare Spider Is Half-Female, Half-Male Split Down The Middle, And Much More This Week
  • Why Do Trains Not Have Seatbelts? It’s Probably Not What You Think
  • World’s Driest Hot Desert Just Burst Into A Rare And Fleeting Desert Bloom
  • Theoretical Dark Matter Infernos Could Melt The Earth’s Core, Turning It Liquid
  • North America’s Largest Mammal Once Numbered 60 Million – Then Humans Nearly Drove It To Extinction
  • North America’s Largest Ever Land Animal Was A 21-Meter-Long Titan
  • A Two-Headed Fossil, 50/50 Spider, And World-First Butt Drag
  • Interstellar Comet 3I/ATLAS Is Losing Buckets Of Water Every Second – And It’s Got Cyanide
  • “A Historic Shift”: Renewables Generated More Power Than Coal Globally For First Time
  • The World’s Oldest Known Snake In Captivity Became A Mom At 62 – No Dad Required
  • Biggest Ocean Current On Earth Is Set To Shift, Spelling Huge Changes For Ecosystems
  • Why Are The Continents All Bunched Up On One Side Of The Planet?
  • Why Can’t We Reach Absolute Zero?
  • “We Were Onto Something”: Highest Resolution Radio Arc Shows The Lowest Mass Dark Object Yet
  • How Headsets Made For Cyclists Are Giving Hearing And Hope To Kids With Glue Ear
  • It Was Thought Only One Mammal On Earth Had Iridescent Fur – Turns Out There’s More
  • Business
  • Health
  • News
  • Science
  • Technology
  • +1 718 874 1545
  • +91 78878 22626
  • [email protected]
Office Address
Prudour Pvt. Ltd. 420 Lexington Avenue Suite 300 New York City, NY 10170.

Powered by Prudour Network

Copyrights © 2025 · Medical Market Report. All Rights Reserved.

Go to mobile version